Critical Survey: Marker Therapeutics (NASDAQ:MRKR) and Madrigal Pharmaceuticals (NASDAQ:MDGL)

Marker Therapeutics (NASDAQ:MRKR) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Risk and Volatility

Marker Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, indicating that its share price is 204% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Marker Therapeutics and Madrigal Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1	0	2	1	2.75
Madrigal Pharmaceuticals	1	2	15	0	2.78

Marker Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 920.41%. Madrigal Pharmaceuticals has a consensus price target of $699.20, indicating a potential upside of 62.47%. Given Marker Therapeutics’ higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Madrigal Pharmaceuticals.

Profitability

This table compares Marker Therapeutics and Madrigal Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	N/A	-56.96%	-47.82%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Insider and Institutional Ownership

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Marker Therapeutics and Madrigal Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55 million	4.60	-$12.16 million	($0.41)	-2.39
Madrigal Pharmaceuticals	$958.40 million	10.37	-$288.28 million	($12.89)	-33.39

Marker Therapeutics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Madrigal Pharmaceuticals beats Marker Therapeutics on 8 of the 15 factors compared between the two stocks.

About Marker Therapeutics

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.